Neuroleptic malignant syndrome (NMS) is a relatively rare and a potentially fatal syndrome. It is a serious complication associated with antipsychotic therapy. NMS is easily prone to pneumonia, rhabdomyolysis and other problems. However, the clinical features of NMS complicated with pneumonia remains largely unclear.
Featured Article of the Month
Articles
-
-
Aberrant synaptophysin expression in classic Hodgkin lymphoma
-
Multidisciplinary collaboration in diagnosis and treatment of neuroleptic malignant syndrome complicated with pneumonia: report of three cases
-
Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue
-
GATA3 expression in clear cell adenocarcinoma of the lower urinary tract: a potential diagnostic pitfall
-
Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited
-
The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody
-
Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring
-
An unusual case of Acanthamoeba Polyphaga and Pseudomonas Aeruginosa keratitis
-
p16 as a diagnostic marker of cervical neoplasia: a tissue microarray study of 796 archival specimens
Global Advances in AI: Innovations in Digital Pathology and Radiology 2022
Kameda Medical Center (Japan), Nagasaki University (Japan) and The Ohio State University (USA) are teaming up to present a virtual joint conference on Global Advances in AI: Innovations in Digital Pathology and Radiology 2022. International speakers will share up-to-date information on AI development in pathology and radiology.
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Top reviewers of 2021
We recognize that our peer reviewers play a pivotal role in maintaining the standard of the journal by critically evaluating our submissions. The editors and staff of Diagnostic Pathology thank our reviewers for their valuable time and efforts. As a token of our appreciation, we would like to publicly recognize the top peer reviewers of 2021.
Joon Hyuk Choi
Michele Alves
Yuichiro Hatano
Vicente Marco Molina
Wei Chen
Yanjun Hou
Helen J. Trihia
Ata Abbasi
Diego Fernando Alzate-Correa
Marius Lund-Iversen
Uma Krishnamurti
Artificial Intelligence in Cancer Imaging and Diagnosis
New tools and technologies such as computational and digital pathology, molecular diagnostics and artificial intelligence (AI) are making their way into advanced clinical diagnostics, providing some unique opportunities to incorporate these tools into the evolving health care landscape. We're proud to present a cross journal series with articles that would give the viewer a perspective of the current trends and future prospects of AI primarily in clinical diagnostics. Read here.
Dr Anil Parwani, Editor-in-Chief
"Diagnostic Pathology has emerged as a premier journal that aims to publish cutting edge articles focused on diagnostic pathology with an emphasis on novel morphological and molecular findings that make an impact on diagnosis of neoplastic and non-neoplastic diseases. The goal of the editorial board and our team is to highlight the cross-roads of diagnostic pathology and new tools and technologies that are exciting, challenging and making an impact on the practice of pathology. We will continue to bring updates in the field of diagnostic pathology by way of novel and interesting case reports, research and original articles and a series of key review articles by experts in the field that will emphasize the new developments which are disease-specific and highlight contemporary and novel technologies that are changing the practice of diagnostic pathology. This is an exciting time in pathology as we are confronted with a new frontier of science and technology which continues to evolve and accelerate the discipline of diagnostic pathology and we wish to take our readers with us on this exciting journey. We want to collaborate with our reviewers and our readers to make Diagnostic Pathology a premier and trusted source of new and exciting developments in the field of diagnostic pathology."
Dr Anil Parwani, Ohio State University
Annual Journal Metrics
-
Citation Impact
3.196 - 2-year Impact Factor (2021)
3.125 - 5-year Impact Factor (2021)
0.93 - Source Normalized Impact per Paper (SNIP)
0.805 - SCImago Journal Rank (SJR)Speed
25 days to first decision for all manuscripts (Median)
48 days to first decision for reviewed manuscripts only (Median)Usage
927,539 Downloads (2021)
367 Altmetric mentions (2021)